MP06-18 phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a RAT model
Abstract
INTRODUCTION AND OBJECTIVES: Many elderly men suffer from benign prostatic hyperplasia (BPH) due to aging, but the pathogenesis of BPH remains to be completely elucidated. Recently, chronic ischemia in the prostate has been suggested to be related to BPH. Thus, we evaluated the impact of chronic ischemia on the development of prostatic hyperplasia and the efficacy of phosphodiesterase type 5 (PDE5) inhibitor for hyperplasia in a rat model with chronic ischemia induced by local atherosclerosis. METHODS: Eighteen male Sprague-Dawley rats weighing 450-500 g were divided into 3 groups: sham operation, regular diet, placebo (SRP group; n = 6); arterial endothelial injury, high cholesterol diet, placebo (AHP group; n = 6); or arterial endothelial injury, high cholesterol diet, and tadalafil as a PDE5 inhibitor (AHT group; n = 6). The endothelial injury in the common iliac arteries was performed using a 2-Fr Fogarty arterial embolectomy catheter through an incision in the femoral artery into the common iliac artery. Diet and oral drugs were administrated for 8 weeks after surgery. At 8 weeks, blood flow to the ventral prostate (VP) was measured using laser speckle blood flow analysis, and the VP was histologically evaluated. RESULTS: Mean VP weights were 639 ± 43 mg in the AHP group and 460 ± 54 mg in the SRP group, showing a significant enlargement in VP for the AHP group compared with the SRP group (p = 0.03). Importantly, mean VP weight was 449 ± 62 mg in the AHT group,…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.